Fabio S Macaluso

List of Publications by Year in Descending Order

86 papers	1,424 citations	20 h-index	34 g-index
92 ext. papers	1,785 ext. citations	4.7 avg, IF	4.87 L-index

#	Paper	IF	Citations
86	Ozanimod for Ulcerative Colitis.. *New England Journal of Medicine*, **2022**, 386, 194	59.2	2
85	Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.. *Inflammatory Bowel Diseases*, **2022**,	4.5	1
84	The key role of colonoscopy at 6 months from ileocolonic resection in Crohn's disease patients. *Digestive and Liver Disease*, **2021**, 53, 517-518	3.3	0
83	SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501. *Journal of Gastroenterology and Hepatology (Australia)*, **2021**, 36, 3041-3049	4	1
82	Vaccinations in patients with inflammatory bowel disease. *Digestive and Liver Disease*, **2021**, 53, 1539-1545	3.3	3
81	Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?. *Gastroenterology*, **2021**, 160, 1877-1878	13.3	6
80	A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease. *Journal of Gastroenterology and Hepatology (Australia)*, **2021**, 36, 105-111	4	7
79	The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches. *Inflammatory Bowel Diseases*, **2021**, 27, 182-189	4.5	19
78	Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. *Therapeutic Advances in Gastroenterology*, **2021**, 14, 17562848211010668	4.7	3
77	Rescue Therapy with Intensive Vedolizumab Optimization in a Seventeen-Year-Old Girl with Acute Severe Ulcerative Colitis. *Digestive Diseases and Sciences*, **2021**, 66, 2470-2471	4	0
76	Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases. *JGH Open*, **2021**, 5, 364-370	1.8	7
75	A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence. *Expert Opinion on Biological Therapy*, **2021**,	5.4	2
74	Letter: propensity score-handle with care. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 360-361	6.1	1
73	A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis. *Digestive and Liver Disease*, **2020**, 52, 1461-1466	3.3	5
72	Herpes Zoster Eruption During Vedolizumab Therapy: A Simple Coincidence or More?. *Inflammatory Bowel Diseases*, **2020**, 26, e51-e52	4.5	0
71	Letter: mesalazine-a safe drug with rare serious adverse events. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 1210-1211	6.1	0
70	JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease. *Current Drug Metabolism*, **2020**, 21, 247-255	3.5	1

69	Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). *Drugs and Aging*, **2020**, 37, 383-392	4.7	12
68	Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies. *Expert Opinion on Biological Therapy*, **2020**, 20, 193-203	5.4	16
67	The VERSIFY Trial: What About Ultrasound Assessment?. *Gastroenterology*, **2020**, 158, 1176-1177	13.3	
66	Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease. *Digestive and Liver Disease*, **2020**, 52, 1304-1309	3.3	5
65	Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). *Expert Opinion on Biological Therapy*, **2020**, 20, 1381-1384	5.4	2
64	Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study. *United European Gastroenterology Journal*, **2020**, 8, 1045-1055	5.3	8
63	COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data. *Digestive and Liver Disease*, **2020**, 52, 1222-1227	3.3	26
62	PhysiciansKnowledge and Application of Immunization Strategies in Patients with Inflammatory Bowel Disease: A Survey of the Italian Group for the Study of Inflammatory Bowel Disease. *Digestion*, **2020**, 101, 433-440	3.6	8
61	Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial. *European Review for Medical and Pharmacological Sciences*, **2020**, 24, 11356-11364	2.9	0
60	Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are insidious adverse events: data from a large single-center cohort. *Scandinavian Journal of Gastroenterology*, **2019**, 54, 1102-1106	2.4	6
59	Prevalence and incidence of inflammatory bowel disease in two Italian islands, Sicily and Sardinia: A report based on health information systems. *Digestive and Liver Disease*, **2019**, 51, 1270-1274	3.3	4
58	Psoriasis and Inflammatory Bowel Disease. *Digestive Diseases*, **2019**, 37, 451-457	3.2	19
57	Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. *Digestive and Liver Disease*, **2019**, 51, 613-620	3.3	8
56	Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. *Inflammatory Bowel Diseases*, **2019**, 25, 1805-1812	4.5	19
55	Letter: psoriasiform eruption during vedolizumab therapy. *Alimentary Pharmacology and Therapeutics*, **2019**, 50, 342-343	6.1	1
54	Anti-TNF combination therapy in inflammatory bowel disease: de novo or selective?. *Minerva Gastroenterologica E Dietologica*, **2019**, 65, 291-297	1.6	2
53	Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis. *Inflammatory Bowel Diseases*, **2019**, 25, 987-997	4.5	10
52	Letter: SPOSIB SB2-a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2. *Alimentary Pharmacology and Therapeutics*, **2019**, 49, 234-236	6.1	8

51	Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease. *Expert Opinion on Biological Therapy*, **2019**, 19, 89-98	5.4	23
50	AISF position paper on HCV in immunocompromised patients. *Digestive and Liver Disease*, **2019**, 51, 10-23	3.3	4
49	Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients. *Infection*, **2019**, 47, 409-415	5.8	3
48	A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease. *Journal of Crohn's and Colitis*, **2019**, 13, 209-217	1.5	19
47	Risk of Pneumonia Caused by Pneumocystis jiroveci in Inflammatory Bowel Disease: The Role of Concomitant Pulmonary Comorbidities. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 571-572	6.9	6
46	The Addition of an Immunosuppressant After Loss of Response to Anti-TNF Monotherapy in Inflammatory Bowel Disease: A 2-Year Study. *Inflammatory Bowel Diseases*, **2018**, 24, 394-401	4.5	9
45	How clinicians and pathologists interact concerning inflammatory bowel disease in Italy: An IG-IBD survey. *Digestive and Liver Disease*, **2018**, 50, 734-736	3.3	2
44	The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. *Digestive and Liver Disease*, **2018**, 50, 675-681	3.3	22
43	Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 1040-1041	6.1	5
42	A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. *Digestive and Liver Disease*, **2018**, 50, 1292-1298	3.3	11
41	Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease. *Journal of Infection*, **2017**, 74, 433-441	18.9	23
40	Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. *Scandinavian Journal of Gastroenterology*, **2017**, 52, 981-987	2.4	15
39	Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease. *Annals of the Rheumatic Diseases*, **2017**, 76, e31	2.4	29
38	The biologics of ulcerative colitis. *Expert Opinion on Biological Therapy*, **2017**, 17, 175-184	5.4	6
37	Screening of colorectal cancer: present and future. *Expert Review of Anticancer Therapy*, **2017**, 17, 1131-1146	3.5	74
36	Is Epstein-Barr virus infection associated with the pathogenesis of microscopic colitis?. *Journal of Clinical Virology*, **2017**, 97, 1-3	14.5	11
35	Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-inhibitors and conventional immunosuppressants. *Digestive and Liver Disease*, **2017**, 49, 157-162	3.3	3
34	Frequency of thiopurine methyltransferase mutation in patients of Mediterranean area with inflammatory bowel disease and autoimmune disorders. *Digestive and Liver Disease*, **2016**, 48, 1506-1509	3.3	6

33	The METEOR Trial: The Burial of Methotrexate in Ulcerative Colitis?. *Gastroenterology*, **2016**, 151, 211-2	13.3	5
32	Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. *Gastroenterology*, **2016**, 150, 145-155.e4; quiz e15-6	13.3	156
31	Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature. *Current Molecular Medicine*, **2016**, 16, 721-737	2.5	12
30	Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort. *Hepatitis Monthly*, **2016**, 16, e31681	1.8	3
29	TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. *Liver International*, **2016**, 36, 198-204	7.9	12
28	The Selective Use of Combination Therapy in Patients with Inflammatory Bowel Disease Resistant to Anti-TNF: to Whom, How and How Long?. *Journal of Crohn's and Colitis*, **2016**, 10, 1451	1.5	7
27	Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2016**, 44, 310-1	6.1	7
26	Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure. *Alimentary Pharmacology and Therapeutics*, **2016**, 43, 1019-20	6.1	0
25	The hepatic expression of vitamin D receptor is inversely associated with the severity of liver damage in genotype 1 chronic hepatitis C patients. *Journal of Clinical Endocrinology and Metabolism* , **2015**, 100, 193-200	5.6	21
24	PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. *Alimentary Pharmacology and Therapeutics*, **2015**, 41, 939-48	6.1	16
23	Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. *Future Microbiology*, **2015**, 10, 977-88	2.9	2
22	The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. *Hepatology*, **2015**, 62, 1101-10	11.2	131
21	Genetic background in nonalcoholic fatty liver disease: A comprehensive review. *World Journal of Gastroenterology*, **2015**, 21, 11088-111	5.6	59
20	Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. *Hepatology*, **2014**, 59, 1692-705	11.2	64
19	Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. *Digestive and Liver Disease*, **2014**, 46, 936-42	3.3	14
18	Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. *Digestive and Liver Disease*, **2014**, 46, 1116-20	3.3	28
17	Cardiovascular diseases and HCV infection: a simple association or more?. *Gut*, **2014**, 63, 369-75	19.2	60
16	Body mass index and liver stiffness affect accuracy of ultrasonography in detecting steatosis in patients with chronic hepatitis C virus genotype 1 infection. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 878-884.e1	6.9	10

15	Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. *Journal of Hepatology*, **2014**, 61, 523-9	13.4	57
14	Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. *Journal of Hepatology*, **2013**, 59, 1169-76	13.4	28
13	Education and Imaging. Hepatobiliary and pancreatic: Portal hypertensive biliopathy presenting as acute cholangitis. *Journal of Gastroenterology and Hepatology (Australia)*, **2013**, 28, 1257	4	2
12	Herbal hepatotoxicity: a hidden epidemic. *Internal and Emergency Medicine*, **2013**, 8, 13-22	3.7	43
11	High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. *Journal of Viral Hepatitis*, **2013**, 20, 174-82	3.4	10
10	Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients. *Journal of Viral Hepatitis*, **2013**, 20, 486-93	3.4	42
9	Metabolic factors and chronic hepatitis C: a complex interplay. *BioMed Research International*, **2013**, 2013, 564645	3	23
8	Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. *World Journal of Hepatology*, **2013**, 5, 685-91	3.4	18
7	Hepatocellular carcinoma and synchronous liver metastases from colorectal cancer in cirrhosis: A case report. *World Journal of Hepatology*, **2013**, 5, 696-700	3.4	5
6	Primary biliary cirrhosis and hereditary hemorrhagic telangiectasia: When two rare diseases coexist. *World Journal of Hepatology*, **2013**, 5, 288-91	3.4	2
5	Progressive multi-organ expression of immunoglobulin G4-related disease: A case report. *World Journal of Hepatology*, **2013**, 5, 336-9	3.4	2
4	Antimitochondrial antibody -M2 positive autoimmune hepatitis during standard of care for chronic hepatitis C. *Hepatology Research*, **2012**, 42, 428-32	5.1	3
3	Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. *Liver International*, **2012**, 32, 1443-50	7.9	15
2	Serum Eglutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. *PLoS ONE*, **2012**, 7, e51165	3.7	24
1	Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. *Liver International*, **2011**, 31, 507-15	7.9	58